https://scholars.lib.ntu.edu.tw/handle/123456789/477478
標題: | Serum interleukin-6 level but not genotype predicts survival after resection in stages II and III gastric carcinoma | 作者: | WEI-CHIH LIAO Lin J.-T. Wu C.-Y. Huang S.-P. MING-TSAN LIN Wu A.S.-H. Huang Y.-J. MING-SHIANG WU |
公開日期: | 2008 | 卷: | 14 | 期: | 2 | 起(迄)頁: | 428-434 | 來源出版物: | Clinical Cancer Research | 摘要: | Purpose: It has been suggested that interleukin-6 (IL-6) is a prognostic indicator for survival in patients with gastric carcinoma, but this has not been proved using survival analysis. In Asians, the -634G allele is associated with increased IL-6 production. The objective of this study was to evaluate the association between serum IL-6 levels, -634G/C polymorphism, and overall survival after resection for gastric carcinoma. Experimental Design: A total of 155 consecutive patients with gastric carcinoma were evaluated. Serum IL-6 levels were analyzed using an enzyme-linked immunoabsorbent assay. Genotype was determined by PCR and restriction fragment length polymorphism. Serum levels and survival were correlated with genotype and clinicopathologic factors. Results: Age and stage, but not -634G/C genotype,were associated with serum IL-6 levels. The median survival for patients with stage II or stage III gastric carcinoma was 1,418 days in patients with low (?13 pg/mL) versus 618 days in patients with high (>13 pg/mL) serum IL-6 levels (P = 0.038). Results of a multivariate analysis showed that serum IL-6 level of >13 pg/mL was a significant predictor of poor survival (hazard ratio, 1.77; 95% confidence interval, 1.07-2.92; P = 0.026). Conclusions: Serum IL-6 level of >13 pg/mL correlates with tumor progression and is an independent predictor of poor survival after resection. In patients with stage II and III gastric carcinoma, serum IL-6 level is more effective than stage as a prognostic indicator. By measuring IL-6, these patients can be divided into two groups with significant differences in survival. The -634G/C polymorphismis not associated with serum IL-6 level or survival. ? 2008 American Association for Cancer Research. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-38949083209&doi=10.1158%2f1078-0432.CCR-07-1032&partnerID=40&md5=f9bd26d9235bca7a498b59caa3e1c154 https://scholars.lib.ntu.edu.tw/handle/123456789/477478 |
ISSN: | 1078-0432 | DOI: | 10.1158/1078-0432.CCR-07-1032 | SDG/關鍵字: | interleukin 6; adult; advanced cancer; aged; article; cancer surgery; cancer survival; early cancer; enzyme linked immunosorbent assay; female; genetic polymorphism; genotype; human; major clinical study; male; overall survival; polymerase chain reaction; prediction; priority journal; restriction fragment length polymorphism; stomach carcinoma; Aged; Disease Progression; Female; Genotype; Humans; Interleukin-6; Linear Models; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Stomach Neoplasms; Survival Rate |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。